Date: 2014-04-30
Type of information: Financing round
Company: Celenys (France)
Investors: Go Capital (France) NCI (France)
Amount: €1 million
Funding type: financing round
Planned used: Celenys is a young innovative company which develops, produces and sells new supports allowing the culture of three-dimensional cells (3D): reticulated hyaluronic hydrogels.Its first product is pre-marketed under the trademark Biomimesys®, allowing customers (academic, cosmetic and pharmaceutical laboratories, CRO and biotechnology companies) to perform 3D cell cultures in an environment more representative of the biological reality than a classical two-dimensional culture. Its primary applications are the screening and predictive toxicology on cancer cell lines cultivated in this biomaterial. The funds raised will allow the company to strengthen its staff (Research & Development and Marketing), carry out necessary investments for production and to ensure the commercial launch of its Biomimesys® range from the end of 2014.
Others: * On April 30, 2014, Celenys has announced it has raised € 1 million. Go Capital has invested 700,000 € in the company in partnership with NCI who is co-investing 300,000 €. The investment from Go Capital is made via the Go Capital Amorçage fund, set up in March 2012 and with the participation of the Haute-Normandie Region amongst others. The NCI investment is made via the ‘Croissance et Proximité 2’ fund. This fund is the partner of start-ups and developing companies in Normandy. NCI carries out a vast range of local professional capital-investment, with more than 110M€ of own funds available to companies based in Normandy and the east of Paris in priority.
Therapeutic area:
